Lucitanib
As of the edition of 20 October 2026, Lucitanib is a small molecule: stopped in 2026; acts on FGFR1, FGFR2 and FLT1 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 12, 5 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
14 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product14 company-target rows are on route A because of Lucitanib.
See the 14 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 9 | 3 | 0 | 5 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Haihe Biopharma | Lead sponsor of trials | 2014 to now |
| Clovis Oncology | Lead sponsor of trials | 2014 to now |
| pharmaand | Lead sponsor of trials | 2019 to now |
| Bristol Myers Squibb | Lead sponsor of trials | 2021 to now |